Onemednet Corp
Onemednet Corp provides industrial services, primarily in the health care technology sector, generating revenue through its operations in business support services.
Business. Onemednet Corp (ONMD.O) is a business support services company operating within the Industrial & Commercial Services sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Onemednet Corp (ONMD.O) is a business support services company operating within the Industrial & Commercial Services sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Onemednet Corp's capital structure is highly leveraged, with total liabilities of $16.45 million and total equity of -$15.70 million, indicating a negative net worth. The company's liquidity position is weak, as reflected by a current ratio of 0.04, suggesting significant short-term financial stress. The enterprise value to revenue ratio of 214.24 is well above the typical range for the industry, indicating a high valuation relative to its revenue base.
Profitability metrics are deeply negative, with a net income of -$2.11 million and an operating income of -$2.10 million. The return on equity of 0.1343 is misleading due to the negative equity base, and the return on assets of -2.812 indicates poor asset utilization. These figures are far below the industry median for profitability and returns, suggesting a company in distress.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks and limits the company's ability to offset losses in one area with gains in another.
Growth trajectory is negative, with no clear signs of improvement in the current fiscal year. The company's operating cash flow is -$1.55 million, and free cash flow is -$2.10 million, indicating a lack of internal cash generation. The capital expenditure of -$6,000 suggests minimal investment in future growth, further signaling a lack of strategic direction.
Risk factors include a high liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is currently low, but the company's negative equity and high debt levels could lead to future dilution if additional financing is required. No recent events or filings have been disclosed that would indicate a change in the company's risk profile.
Recent events and filings do not show any significant developments that would alter the company's current financial or operational status. The absence of recent positive news or strategic moves suggests a lack of momentum and potential for recovery.
- Onemednet Corp is operating at a significant loss, with a negative net income and operating income.
- The company's capital structure is highly leveraged, with total liabilities exceeding total assets.
- The company's liquidity position is weak, as indicated by a very low current ratio.
- The company's valuation is extremely high relative to its revenue, suggesting a disconnect between market perception and financial performance.
- The company lacks geographic and segment diversification, increasing its exposure to sector-specific risks.
- The company's growth trajectory is negative, with no signs of improvement in the current fiscal year.
Bull / Bear case
Generated · model-assistedRevenue surged 111.4% year-over-year to $1.36 million, demonstrating significant top-line growth momentum in the latest fiscal period.
Net income improved by 72.3% year-over-year, indicating a substantial reduction in losses compared to the prior fiscal year.
Free cash flow improved by 57.8% year-over-year, reflecting better cash generation capabilities despite ongoing negative flows.
Dilution risk is assessed as low, providing some stability for existing shareholders regarding potential equity issuance impacts.
The company faces high credit risk and medium liquidity risk, signaling potential difficulties in meeting short-term financial obligations.
Operating margin of -8.47% places the company in the bottom quartile of its business support services cohort.
Net margin of -8.50% ranks in the bottom quartile among 381 peers, highlighting persistent profitability challenges.
A current ratio of 0.43 indicates severe liquidity constraints, as current assets cover less than half of current liabilities.
Cash conversion of 0.73 is below the cohort median of 1.15, suggesting weaker efficiency in converting earnings to cash.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Onemednet Corp Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Aaron GreenPresident, Chief Executive Officer, Director
Insider activity
- Director, Chief Executive Officer · Common StockBought 36 650 @ $0,57$21K · 2026-06-23
- Director, Chief Medical Officer, 10% owner · Common StockBought 158 730 @ $0,63$100K · 2026-06-23
- Director, Chief Medical Officer, 10% owner · Common StockBought 172 414 @ $0,58$100K · 2026-06-16
- Director, Chief Executive Officer · Common StockBought 18 702 @ $0,54$10K · 2026-06-15
- Director, Chief Executive Officer · Common StockBought 36 920 @ $0,56$21K · 2026-06-12
- Director, 10% owner · Common StockBought 158 730 @ $0,63$100K · 2026-06-12
- Director, 10% owner · Common StockBought 268 817 @ $0,93$250K · 2026-05-18
- Director, 10% owner · Common StockBought 280 898 @ $0,89$250K · 2026-04-23
- Director, Chief Medical Officer, 10% owner · Common StockBought 903 614 @ $0,83$750K · 2026-04-01
- Director, Chief Medical Officer, 10% owner · Common StockOther 219 429 @ $0,83$182K · 2026-04-01
- Director, 10% owner · Common StockBought 595 238 @ $0,84$500K · 2026-02-06
- Director, Chief Financial Officer · Common StockOther 45 000 · 2025-11-26
- Director · Common StockOther 38 219 · 2025-11-26
- Director · Common StockOther 45 000 · 2025-11-26
- Director · Common StockOther 45 000 · 2025-11-26
- Director · Common StockOther 45 000 · 2025-11-26
- Director, Chief Medical Officer · Common StockOther 45 000 · 2025-11-26
- Director · Common StockOther 45 000 · 2025-11-26
- Director, Chief Executive Officer · Common StockOther 45 000 · 2025-11-26
- Director · Common StockOther 45 000 · 2025-11-26
- Director, Chief Financial Officer · Common StockOther 300 000 · 2025-11-24
- Director, Chief Medical Officer · Common StockOther 200 000 · 2025-11-24
- Director, Chief Financial Officer · Common StockOther 33 333 · 2025-11-24
- Director, Chief Executive Officer · Common StockOther 1 000 000 · 2025-11-24
- Director, Chief Executive Officer · Common StockSold 61 555 @ $1,20$74K · 2025-11-18
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating income (YoY) (2025-12-31 vs 2024-12-31): -0.6%Derived (calculated)
- Net margin (FY 2025-12-31): -206.1%Derived (calculated)
- Gross margin (FY 2025-12-31): -37.0%Derived (calculated)
- Return on equity (FY 2025-12-31): 94.5%Derived (calculated)
- Return on assets (FY 2025-12-31): -130.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.43xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): -1.73xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -74.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 240.1%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 101.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 83.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 83.3%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -79.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 72.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -7.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 3.3%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 111.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 81.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -42.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -74.0%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -90.5%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Total operating expenses (annual): USD 9.16MSEC XBRL filing
- Pre-tax income (annual): USD -2.8MSEC XBRL filing